Artificial Intelligence in Drug Repurposing Market (2022 to 2035)

Artificial Intelligence in Drug Repurposing Market Summary:

The global Artificial Intelligence in Drug Repurposing Market size was valued at USD 1424.5 million in 2025 and is projected to reach USD 14481.5 million by 2035, expanding at a CAGR of 28.30% from 2026 to 2035. The growth during the forecast period is driven by the increasing AI and biopharmaceutical collaborations, rising demand for faster and cost-effective drug development, and growing adoption of machine learning and deep learning platforms for drug repurposing.

Years	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
Revenue (USD Mn)	710.4	XX	XX	1424.5	XX	XX	XX	XX	XX	XX	XX	XX	XX	14481.5

Key Market Takeaways & Insights

• North America Artificial Intelligence in Drug Repurposing Market held the largest share of 54.00% of the global market in 2025.
• The Artificial Intelligence in Drug Repurposing industry in the Asia Pacific is expected to grow significantly over the forecast period.
• By Technology, the Machine Learning/Deep Learning segment held the largest market share of 41% in 2025.
• By Application, Oncology segment held the largest market share in 2025.
• By End User, the Pharmaceutical & Biotechnology Companies segment held the largest market share in 2025.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Artificial Intelligence in Drug Repurposing Market Size: USD 1424.5 Million
• 2035 Artificial Intelligence in Drug Repurposing Market Size: USD 14481.5 Million
• Artificial Intelligence in Drug Repurposing Market CAGR (2026-2035): 26.10%

Region

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

North America

XX

XX

XX

769.23

XX

XX

XX

XX

XX

XX

XX

XX

XX

6558.0

Europe

XX

XX

XX

313.39

XX

XX

XX

XX

XX

XX

XX

XX

XX

2781.6

Asia Pacific

XX

XX

XX

259.26

XX

XX

XX

XX

XX

XX

XX

XX

XX

3084.8

Middle East and Africa

XX

XX

XX

44.16

XX

XX

XX

XX

XX

XX

XX

XX

XX

414.6

Latin America

XX

XX

XX

38.46

XX

XX

XX

XX

XX

XX

XX

XX

XX

381.8

Disease Epidemiology Analysis:

• AI-driven drug repurposing trends
• Pipeline optimization analysis
• Data integration assessment
• Strategic collaboration overview

Treatment Landscape Overview:

• Current standard-of-care and therapeutic pathway assessment
• Existing drug pipeline and lifecycle management analysis
• Unmet clinical needs and treatment gap evaluation
• AI-enabled drug repurposing opportunity mapping by indication

	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
Conservative	1424.5	XX	XX	XX	XX	XX	XX	XX	XX	XX	12441.6
Likely	1424.5	XX	XX	XX	XX	XX	XX	XX	XX	XX	14481.4
Optimistic	1424.5	XX	XX	XX	XX	XX	XX	XX	XX	XX	19487.4

Market Dynamics:
Market Drivers:

Rising AI and Biopharmaceutical Collaborations Accelerating Drug Repurposing Market Growth

Increasing Al and biopharmaceutical collaborations to reduce drug development timelines is a key factor driving market growth. They convert AI repurposing into validated, decision-ready programs. Several pharmaceutical and biotechnology companies have compound libraries, biological samples, and clinical context, whereas Al vendors provide scalable algorithms for hypothesis generation, ranking, and biomarker-led prioritization. A strategic collaboration between these organizations shortens the time and cost required to progress from computational prediction to wet-lab confirmation and early clinical proof-of-concept. These collaborations help to overcome the adoption barrier. Partnerships accelerate deployment, expand repurposable assets, and create repeatable pipelines, ultimately strengthening commercial demand for platforms and services.

In February 2026, Merck collaborated with Mayo Clinic to apply artificial intelligence (Al), advanced analytics, and multimodal clinical data to support drug discovery and development. Such developments are driving market growth. 

Rising Demand for Faster and Cost-Effective Drug Development

The growing need to reduce drug development timelines and lower costs is a major driver of the Artificial Intelligence in Drug Repurposing Market. Traditional drug discovery processes are costly, time-consuming, and have a high failure rate. AI-powered repurposing platforms aid in the discovery of new therapeutic applications for existing drugs by analyzing biological, clinical, and molecular datasets more efficiently. These technologies speed up candidate screening, improve prediction accuracy, and reduce early-stage research costs. Pharmaceutical and biotechnology companies are increasingly using AI to boost pipeline productivity and optimize research investments. The growing emphasis on faster commercialization and more efficient drug development is helping to drive market expansion.

Market Restraint:

Data Availability and Governance Challenges Restraining AI in Drug Repurposing Market Growth

Data availability and governance issues are significant challenges for Al in the drug repurposing market. Repurposed models rely heavily on data availability and are only as powerful as the clinical, molecular, and literature evidence they can learn from and validate. Their efficiency is hampered by fragmented datasets across geographies and systems, limited patient-level data access, inconsistent coding and ontology standards, and stringent security requirements. This slows model training and validation, reduces output confidence, and delays platform adoption.

For instance, in February 2025, TriNetX warned in a survey that, while RWD and Al are priorities, data compatibility, regulatory hurdles, and security concerns are looming barriers that can stall momentum, reflecting the governance and interoperability constraints that are impeding adoption. Such factors impede development.

Limited Interpretability of AI Models Restricting Adoption

Limited transparency and interpretability of AI models are significant barriers to the Artificial Intelligence in Drug Repurposing Market. Many advanced machine learning and deep learning systems use "black box" models, making it difficult for researchers and regulatory authorities to understand how predictions are made. This lack of explainability undermines trust in AI-based recommendations for drug candidate selection and clinical decision-making. Regulatory agencies and healthcare organizations frequently require clear scientific justification before approving repurposed therapies. As a result, concerns about reliability, validation, and regulatory acceptance impede the implementation of advanced AI technologies in drug repurposing applications.

Market Opportunities:

Growing Adoption of Scalable AI Platforms Creating Opportunities in the Drug Repurposing Market

Market growth opportunities for Al in drug repurposing are expanding as the industry transitions from one-time academic exercises to repeatable, scalable platforms capable of continuously mining new evidence and converting it into prioritized, validation-ready candidates. As pharmaceutical and biotech companies look to improve pipe productivity, there is a significant opportunity for solutions that (i) industrialize portfolio-wide repurposing of acr approved and shelved assets, (ii) integrate real-world and multimodal data to strengthen clinical relevance, and (iii) support faster proof-of-concept execution through cohort discovery, biomarker strategy, and trial design enablement. Improved data integration and scalable platforms boost decision-making confidence, leading to increased adoption, enterprise contracts, and partnership-led repurposing programs.

For instance, in September 2025, Eli Lilly launched Lilly TuneLab, an AI/ML platform that provides biotechnology companies with drug discovery models trained on Lilly research data. 

Growing Integration of Real-World and Multimodal Data

The increasing integration of real-world and multimodal data creates a significant opportunity for the Artificial Intelligence in Drug Repurposing Market. AI platforms are increasingly combining genomic data, electronic health records, clinical outcomes, medical imaging, and scientific literature to better identify and validate drug candidates. This integrated approach improves prediction accuracy and clinical relevance in repurposing programs. Pharmaceutical companies are investing in advanced data analytics platforms to help them develop precision medicine and targeted therapies. Expanding access to diverse healthcare datasets, as well as advancements in cloud-based AI infrastructure, are expected to open up new commercial opportunities and accelerate the adoption of AI-driven repurposing solutions.

By Technology	2025
Machine Learning/Deep Learning	41%
Natural Language Processing (NLP)	28%
Knowledge Graphs & Network-Based AI	17%
Generative AI & Large Language Models (LLMs)	10%
Computer Vision	4%

Artificial Intelligence in Drug Repurposing Market Segmentations Analysis:

By Technology, Machine Learning and Deep Learning Segments Dominate the Artificial Intelligence in Drug Repurposing Market

The machine learning and deep learning segments are expected to dominate the market as repurposing necessitates pattern recognition across diverse signals such as text, structured biology, networks, and patient-level data. These models can improve ranking precision as new data arrives and enable continuous learning loops as validation results are fed back into the system. The technology prioritizes candidates and forecasts results. Many key companies are focusing on strategic alliances to capitalise on market growth opportunities. For example, in May 2024, Sanofi, Formation Bio, and OpenAl collaborated to create Al-powered software to speed up drug development and bring new medicines to patients more efficiently. Such developments are expected to boost segmental growth. 

The generative AI and large language models (LLMs) segment are expected to grow the fastest from 2025 to 2035. The Generative AI and LLMs segment are revolutionizing drug repurposing by enabling rapid hypothesis generation and molecular design using advanced natural-language and generative-modeling technologies. LLMs can examine extensive biomedical literature, clinical trial records, and omics data to identify connections between existing drugs and new disease indications. Generative AI improves this process by creating novel molecular variations and predicting drug-disease interactions with high accuracy. These tools reduce the time required for manual curation, resulting in a scalable framework for identifying repurposing opportunities.

By Component, Software & Platform Segment Dominates the Market Through Scalable and Integrated Drug Repurposing Workflows.

The software & platform segment is expected to have a dominant market share. The large share is expected due to these platforms' repeatable, scalable applications for repurposing across multiple assets. These platforms combine data ingestion, hypothesis generation, scoring, and evidence packaging into a single workflow, resulting in shorter cycle times and more consistent decisions across therapeutic areas. Strategic collaborations between pharmaceutical and research groups are expected to increase the segment's productivity.

For example, in April 2024, BioPhy collaborated with Every Cure to maximize the potential of existing medicines to treat every disease and patient. The collaboration focused on the simulation and optimization of clinical trials and endpoints, with the goal of increasing trial success rates and making better use of capital. Such developments are expected to drive segment growth. 

The services segment is expected to grow at the fastest CAGR over the forecast period. The services segment includes specialized offerings that help with the implementation, customization, and optimization of AI solutions for drug repurposing. These include data curation, annotation, algorithm training, model validation, and the incorporation of AI tools into existing research workflows. Service providers also assist with regulatory compliance, ensuring that AI-driven predictions are consistent with evolving drug development guidelines. Furthermore, services are becoming more focused on collaborative projects that combine biological domain expertise with advanced computational capabilities, which is driving market growth even further.

Oncology Hold the Largest Share in the Market

Oncology is the leading application, accounting for a majority of share in the market, as cancer remains one of the most difficult and expensive diseases to manage. AI-powered platforms are being used to identify new indications for existing oncology drugs, discover novel drug combinations, and predict patient responses, all of which help to accelerate the development of more effective and personalized cancer therapies. The ability to repurpose drugs with established safety profiles is especially useful in oncology, where timely access to new treatments can significantly improve patient outcomes.

The infectious diseases segment is expected to grow at the fastest CAGR from 2025 to 2035. AI is being used to repurpose drugs for combating infectious diseases and antimicrobial resistance, with computational models analyzing existing drug libraries, host pathogen interactions, and large biomedical datasets to identify promising therapeutic candidates. The December 2024 article "Artificial Intelligence for Drug Repurposing Against Infectious Diseases" describes how AI-based virtual screening, predictive modeling, and data integration approaches accelerate the identification of potential therapies by leveraging the known safety profiles of existing drugs, saving time and money when compared to traditional drug discovery.

Pharmaceutical & Biotechnology Companies Dominate the End-User Market

The pharmaceutical and biotechnology company segment is expected to dominate the market. The segment's dominance is attributed to high spending because they control the largest asset portfolios and have the strongest commercial incentives. They also have validation infrastructure and clinical development operations in place to convert Al results into experiments and trials. Such factors directly increase their investments, thereby promoting market growth. For example, in September 2023, Merck partnered with BenevolentAl and Exscientia to accelerate drug discovery with a higher chance of success. The collaboration aimed to generate new development candidates for oncology, neurology, and immunology. Such developments are expected to boost segmental growth. 

The academic and research institutes segment is expected to expand significantly during the forecast period. These institutions use extensive biomedical data and computational expertise to create novel AI methodologies that speed up drug repurposing efforts. Their primary focus is algorithm development, predictive modeling, and multi-omics data integration, which allows for the highly precise identification of potential therapeutic candidates. Furthermore, academic and research institutes are critical partners for pharmaceutical companies and AI startups, bridging the gap between scientific discovery and commercialization.

Market Regional Insights:

By Geography	2022	2025	2035
North America	XX	769.23	6558
US	XX	712.31	XX
Canada	XX	56.92	XX
Europe	XX	313.39	4292.9
Germany	XX	64.24	XX
UK	XX	40.11	XX
France	XX	48.89	XX
Italy	XX	26.95	XX
Spain	XX	25.70	XX
Switzerland	XX	9.72	XX
Netherlands	XX	6.58	XX
Rest of Europe	XX	91.20	XX
Asia Pacific	XX	259.26	3084.8
China	XX	108.63	XX
India	XX	19.70	XX
Japan	XX	40.96	XX
South Korea	XX	37.07	XX
Singapore	XX	9.33	XX
Australia	XX	13.48	XX
Thailand	XX	3.37	XX
Malaysia	XX	6.48	XX
Philippines	XX	5.19	XX
Indonesia	XX	4.15	XX
Rest of Asia Pacific	XX	10.89	XX
Middle East & Africa	XX	44.16	414.6
Saudi Arabia	XX	14.48	XX
United Arab Emirates	XX	11.44	XX
South Africa	XX	6.67	XX
Egypt	XX	3.62	XX
Israel	XX	3.18	XX
Rest of MEA	XX	4.77	XX
Latin America	XX	38.46	381.8
Brazil	XX	12.65	XX
Mexico	XX	9.04	XX
Argentina	XX	4.08	XX
Chile	XX	3.31	XX
Colombia	XX	2.00	XX
Peru	XX	1.65	XX
Rest of LA	XX	5.73	XX

North America Artificial Intelligence in Drug Repurposing Market Analysis:

North America Artificial Intelligence in Drug Repurposing Market held the largest share of 54.00% of the global market in 2025 and was valued at approximately USD 769.23 million. The regional market is primarily driven by the strong adoption of AI in pharmacovigilance systems and growing integration of electronic health records with AI.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 North America Artificial Intelligence in Drug Repurposing Market Size: USD 769.23 Million
• 2035 North America Artificial Intelligence in Drug Repurposing Market Size: USD 6558 million
• North America Artificial Intelligence in Drug Repurposing Market CAGR (2026-2033): 23.9%

Drivers

• Increasing use of real-world clinical data analytics
• Rising demand for faster drug lifecycle extension
• Growing integration of electronic health records with AI

Restraints

• Data interoperability issues across healthcare systems
• High validation requirements for repurposed drug approvals
• Concerns over algorithm bias in clinical decisions

Opportunities

• Expansion of AI-driven orphan drug repurposing
• Rising use of AI in post-market drug optimization

United State Artificial Intelligence in Drug Repurposing Market Analysis:

The U.S. accounted for the dominant share within North America and represented approximately 23.7% of the regional market in 2025. The U.S. Artificial Intelligence in Drug Repurposing Market was valued at nearly USD 712.31 million, supported by increasing use of AI in electronic health record mining.

Drivers

• Strong availability of large-scale real-world patient datasets
• Increasing use of AI in electronic health record mining
• Rising adoption of predictive modeling in drug lifecycle management
• Expanding pharma–tech ecosystem collaborations

Restraints

• High regulatory scrutiny for off-label drug applications
• Data ownership and sharing restrictions among institutions
• Complexity in validating AI-derived repurposing insights

Opportunities

• Growth in AI-based rare disease drug repositioning
• Rising use of AI for oncology drug reuse studies
• Expansion of hospital-led AI drug discovery networks

Canada Artificial Intelligence in Drug Repurposing Market Analysis:

Canada represented approximately 25.2% of the North American market in 2025 and was valued at around USD 56.92 million. The market is witnessing steady growth due to expanding use of machine learning in clinical decision support.

Drivers

• Increasing national focus on health data digitization
• Growing adoption of AI in public healthcare systems
• Rising research collaborations between universities and hospitals

Restraints

• Limited access to large unified patient databases
• Slow integration of AI into public healthcare infrastructure
• Shortage of specialized AI healthcare talent

Opportunities

• Rising cross-border research collaborations with global pharma
• Increasing adoption of AI in personalized drug reuse strategies

Europe Artificial Intelligence in Drug Repurposing Market Analysis:

Europe accounted for approximately 22.00% of the global Artificial Intelligence in Drug Repurposing Market in 2025 and was valued at nearly USD 313.39 million. The market benefits from strong growth in AI-enabled biomedical research programs,

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Europe Artificial Intelligence in Drug Repurposing Market Size: USD 313.39 Million
• 2035 Europe Artificial Intelligence in Drug Repurposing Market Size: USD 2781.6 million
• Europe Artificial Intelligence in Drug Repurposing Market CAGR (2026-2033): 24.4%

Drivers

• Increasing utilization of cross-country healthcare databases
• Rising focus on value-based drug development strategies
• Strong growth in AI-enabled biomedical research programs
• Expanding adoption of computational pharmacology tools

Restraints

• Strict multi-country data governance regulations
• Fragmented healthcare systems across regions
• High complexity in cross-border clinical data integration

Opportunities

• Growth in AI-driven multi-disease drug repositioning
• Rising EU-funded collaborative research initiatives
• Expansion of AI use in aging-related disease treatment discovery

United KingdomArtificial Intelligence in Drug Repurposing Market Analysis

The UK represented approximately 23.6% of the European market in 2025 and was valued at nearly USD 40.11 million. The market is supported by increasing focus on cost-efficient drug development.

Drivers

• Strong NHS digital health data utilization
• Rising adoption of AI in clinical evidence generation
• Increasing focus on cost-efficient drug development
• Expanding pharma–academic research collaborations

Restraints

• Complex patient data access approval processes
• Limited interoperability between NHS systems
• Ethical concerns in secondary use of health data

Opportunities

• Growth in AI-based oncology drug repositioning
• Rising use of AI for neurodegenerative disease therapies
• Expansion of national AI health innovation programs

GermanyArtificial Intelligence in Drug Repurposing Market Analysis

Germany accounted for approximately 25.2% of the European market in 2025 and was valued at around USD 64.24 million. The country remains a key European hub for increasing adoption of industrial AI in life sciences and rising investment in computational drug analytics.

Drivers

• Strong pharmaceutical manufacturing ecosystem
• Increasing adoption of industrial AI in life sciences
• Rising investment in computational drug analytics
• Expanding use of AI in clinical research networks

Restraints

• Strict compliance under EU data protection rules
• High integration complexity in hospital systems
• Limited agility in legacy healthcare infrastructure

Opportunities

• Rising focus on AI for metabolic disease treatments
• Expansion of public–private digital health initiatives

FranceArtificial Intelligence in Drug Repurposing Market Analysis

The France accounts for approximately 24.6% of the European market in 2025 and is valued at nearly USD 48.89 million. The market is supported by increasing adoption of national AI healthcare strategies.

Drivers

• Increasing adoption of national AI healthcare strategies
• Rising use of AI in clinical trial data mining
• Strong academic research in computational biology
• Expanding digital transformation in hospitals

Restraints

• Fragmented healthcare data ecosystems
• High regulatory burden on medical AI applications
• Limited scalability of AI pilots

Opportunities

• Growth in AI-based anti-infective drug repositioning
• Rising EU-funded biomedical innovation programs
• Expansion of AI in inflammatory disease research

ItalyArtificial Intelligence in Drug Repurposing Market Analysis

Italy accounted for approximately 23.8% of the European market in 2025 and was valued at around USD 26.95 million. The country remains a key European hub for increasing focus on reducing healthcare costs.

Drivers

• Growing use of AI in academic medical research
• Increasing focus on reducing healthcare costs
• Rising adoption of predictive analytics in pharma
• Expanding clinical research collaborations

Restraints

• Limited digital maturity in regional hospitals
• Slow regulatory approval for AI tools
• Lack of integrated patient data platforms

Opportunities

• Expansion of AI in oncology drug reuse
• Rising demand for AI in rare disease therapies
• Growth in national biomedical innovation programs

SpainArtificial Intelligence in Drug Repurposing Market Analysis

The Spain represented approximately 23.5% of the European market in 2025 and was valued at nearly USD 25.70 million. The market is supported by increasing investment in health innovation ecosystems and rising adoption of AI in hospital networks.

Drivers

• Increasing investment in health innovation ecosystems
• Rising adoption of AI in hospital networks
• Expanding pharmaceutical R&D activities
• Growing focus on digital health transformation

Restraints

• Budget constraints in public healthcare systems
• Limited interoperability of medical databases
• Slow adoption of advanced AI tools

Opportunities

• Growth in AI-supported infectious disease repurposing
• Rising participation in EU health research projects
• Expansion of AI-based personalized treatment research

Switzerland Artificial Intelligence in Drug Repurposing Market Analysis

Switzerland accounted for approximately 24.5% of the European market in 2025 and was valued at around USD 9.72 million. The country remains a advanced clinical research infrastructure

Drivers

• Strong global pharmaceutical headquarters presence
• High investment in precision medicine research
• Advanced clinical research infrastructure
• Increasing use of AI in drug lifecycle analysis

Restraints

• High cost of AI implementation in pharma R&D
• Strict regulatory and compliance environment
• Limited domestic patient data scale

Opportunities

• Growth in AI-based immunology drug repurposing
• Rising partnerships with global biotech firms
• Expansion of AI-driven rare disease research

Netherlands Artificial Intelligence in Drug Repurposing Market Analysis

The Netherlands represented approximately 24.2% of the European market in 2025 and was valued at nearly USD 6.58 million. The market is supported by increasing use of AI in population health analytics.

Drivers

• Strong digital health infrastructure
• Increasing use of AI in population health analytics
• Rising collaboration between universities and pharma
• Expanding focus on data-driven healthcare innovation

Restraints

• Data privacy restrictions under EU regulations
• Limited scale of national clinical datasets
• Integration challenges across healthcare systems

Opportunities

• Rising EU-funded collaborative AI projects
• Expansion of AI in preventive medicine research

Asia Pacific Artificial Intelligence in Drug Repurposing Market Analysis

Asia-Pacific accounted for approximately 18.2% of the global market in 2025 and was valued at nearly USD 259.26 million. Increasing adoption of AI in pharmaceutical analytics and rising investment in cloud-based biomedical research are significantly contributing to regional growth.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Asia Pacific Artificial Intelligence in Drug Repurposing Market Size: USD 259.26 Million
• 2035 Asia Pacific Artificial Intelligence in Drug Repurposing Market Size: USD 3084.8 Million
• Asia Pacific Artificial Intelligence in Drug Repurposing Market CAGR (2026-2033): 28.1%

Drivers

• Rapid expansion of digital health ecosystems
• Increasing adoption of AI in pharmaceutical analytics
• Rising investment in cloud-based biomedical research
• Growing demand for cost-effective drug development

Restraints

• Uneven digital infrastructure across countries
• Limited access to standardized clinical datasets
• High complexity in multi-language data integration

Opportunities

• Growth in AI-based infectious disease repurposing
• Rising expansion of regional biotech innovation hubs

China Artificial Intelligence in Drug Repurposing Market Analysis

China represented approximately 27.6% of the Asia-Pacific market in 2025 and was valued at around USD 108.63 million. The market is expanding rapidly due to the strong integration of AI in pharmaceutical pipelines, and rapid growth of domestic biotech innovation clusters.

Drivers

• Large-scale national healthcare data digitization
• Strong integration of AI in pharmaceutical pipelines
• Rapid growth of domestic biotech innovation clusters
• Increasing use of AI in traditional medicine studies

Restraints

• Data governance and compliance limitations
• High complexity in integrating multi-source datasets
• Concerns over algorithm transparency

Opportunities

• Expansion of AI in antiviral drug repositioning
• Rising focus on chronic disease treatment optimization
• Growth in AI-enabled precision therapeutics

India Artificial Intelligence in Drug Repurposing Market Analysis:

India accounted for approximately 30.0% of the Asia-Pacific market in 2025 and was valued at nearly USD 19.70 million. Growing pharmaceutical outsourcing and R&D services and rising AI startup activity in healthcare sector are driving market expansion across the country.

Drivers

• Expanding digital health and telemedicine adoption
• Growing pharmaceutical outsourcing and R&D services
• Rising AI startup activity in healthcare sector
• Increasing use of cloud-based clinical data platforms

Restraints

• Limited integration of national health databases
• Infrastructure gaps in advanced computing systems
• Shortage of trained AI healthcare specialists

Opportunities

• Growth in AI-based affordable drug repositioning
• Rising focus on infectious disease repurposing
• Expansion of global pharma collaboration networks

Japan Artificial Intelligence in Drug Repurposing Market Analysis

Japan represented approximately 26.6% of the Asia-Pacific market in 2025 and was valued at around USD 40.96 million. The market is characterized by growth in advanced pharmaceutical and robotics integration.

Drivers

• Strong adoption of AI in aging-related disease research
• Advanced pharmaceutical and robotics integration
• Increasing computational biology investments
• High-quality clinical research infrastructure

Restraints

• Slow adoption in legacy healthcare systems
• High operational costs of AI deployment
• Limited data interoperability across institutions

Opportunities

• Growth in AI-driven neurodegenerative disease repurposing
• Rising use of AI in regenerative medicine research
• Expansion of precision medicine applications

South Korea Artificial Intelligence in Drug Repurposing Market Analysis

South Korea represented approximately 27.2% of the Asia-Pacific market in 2025 and was valued at around USD 37.07 million. The market is expanding rapidly due to strong government support for AI innovation and growing biotech–tech convergence ecosystem.

Drivers

• Rapid digital transformation in healthcare sector
• Strong government support for AI innovation
• Growing biotech–tech convergence ecosystem
• Increasing clinical AI research investments

Restraints

• Limited large-scale validated clinical datasets
• Dependence on imported AI technologies
• Data security and privacy concerns

Opportunities

• Expansion of AI in oncology drug repurposing
• Rising development of smart hospital systems
• Growth in AI-based genomics research

Singapore Artificial Intelligence in Drug Repurposing Market Analysis:

Singapore accounted for approximately 28.4% of the Asia-Pacific market in 2025 and was valued at nearly USD 9.33 million. Advanced digital health infrastructure and increasing global pharma partnerships are driving market expansion across the country.

Drivers

• Strong biomedical research funding ecosystem
• Advanced digital health infrastructure
• Increasing global pharma partnerships
• High adoption of AI in clinical analytics

Restraints

• Small domestic patient population data
• High cost of AI infrastructure deployment
• Reliance on international research collaborations

Opportunities

• Rising biotech innovation hub development
• Expansion of cross-border data collaboration projects

Australia Artificial Intelligence in Drug Repurposing Market Analysis

Australia represented approximately 27.4% of the Asia-Pacific market in 2025 and was valued at around USD 13.48 million. The market is characterized by growing investment in health innovation programs.

Drivers

• Strong academic research capabilities in life sciences
• Increasing use of AI in biomedical informatics
• Growing investment in health innovation programs
• Rising adoption of AI in drug screening

Restraints

• Limited commercialization of AI research outputs
• High cost of healthcare AI integration
• Shortage of specialized AI professionals

Opportunities

• Growth in government-funded digital health projects
• Rising adoption of predictive healthcare analytics

Thailand Artificial Intelligence in Drug Repurposing Market Analysis

Thailand represented approximately 28.2% of the Asia-Pacific market in 2025 and was valued at around USD 3.37 million. The market is expanding rapidly due to growing pharmaceutical sector expansion.

Drivers

• Increasing healthcare modernization initiatives
• Rising adoption of digital medical research tools
• Growing pharmaceutical sector expansion
• Expanding awareness of AI in healthcare

Restraints

• Limited R&D funding for advanced AI systems
• Lack of unified healthcare data platforms
• Insufficient AI-skilled workforce

Opportunities

• Rising international research collaborations
• Expansion of digital clinical research systems

Malaysia Artificial Intelligence in Drug Repurposing Market Analysis:

Malaysia accounted for approximately 27.9% of the Asia-Pacific market in 2025 and was valued at nearly USD 6.48 million. Rising use of cloud-based health platforms and increasing demand for nutrition personalization are driving market expansion across the country.

Drivers

• Growing healthcare digital transformation
• Increasing biotech and pharma investments
• Rising adoption of AI analytics tools

Restraints

• Data privacy and compliance challenges
• Dependence on foreign technology providers

Opportunities

• Rising healthcare startup ecosystem growth
• Increasing regional research partnerships

Philippines Artificial Intelligence in Drug Repurposing Market Analysis

Philippines represented approximately 28.3% of the Asia-Pacific market in 2025 and was valued at around USD 5.19 million. The market is characterized by advanced healthcare systems and high adoption of technologically sophisticated diagnostic solutions.

Drivers

• Increasing interest in AI-based drug research
• Expanding pharmaceutical collaboration initiatives
• Rising healthcare modernization efforts

Restraints

• Limited access to advanced computing infrastructure
• Shortage of trained AI professionals
• Weak integration of healthcare data systems

Opportunities

• Rising global partnerships in healthcare AI
• Expansion of cloud-based clinical research tools

Indonesia Artificial Intelligence in Drug Repurposing Market Analysis

Indonesia represented approximately 28.7% of the Asia-Pacific market in 2025 and was valued at around USD 4.15 million. The market is expanding rapidly due to rising nutrition awareness and gowing chronic disease burden.

Drivers

• Increasing pharmaceutical sector development
• Growing use of AI in medical research
• Rising investment in life sciences innovation

Restraints

• Regulatory fragmentation in healthcare systems
• Lack of standardized clinical datasets

Opportunities

• Rising biotech startup ecosystem development
• Expansion of AI-driven drug discovery initiatives

Middle East & AfricaArtificial Intelligence in Drug Repurposing Market Analysis

Middle East & Africa accounted for approximately 3.10% of the global market in 2025 and was valued at nearly USD 44.16 Million. The market is gradually expanding due to increasing demand for nutrition personalization and growing awareness of gut health management.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Middle East & Africa Artificial Intelligence in Drug Repurposing Market Size: USD 44.16 Million
• 2035 Middle East & Africa Artificial Intelligence in Drug Repurposing Market Size: USD 414.6 Million
• Middle East & Africa Artificial Intelligence in Drug Repurposing Market CAGR (2026-2033): 25.1%

Drivers

• Increasing adoption of AI-enabled healthcare platforms
• Rising investment in regional life sciences development
• Growing use of digital clinical research tools
• Expanding focus on data-driven healthcare decision systems

Restraints

• Limited access to advanced biomedical data infrastructure
• Shortage of AI-skilled healthcare professionals
• Fragmented healthcare systems across countries

Opportunities

• Rising international collaborations in drug research
• Expansion of AI-supported public health innovation programs

Saudi Arabia Artificial Intelligence in Drug Repurposing Market Analysis:

Saudi Arabia accounted for approximately 25.7% of the Asia-Pacific market in 2025 and was valued at nearly USD 14.48 million. Increasing integration of AI in hospital systems and strong national focus on pharmaceutical innovation are driving market expansion across the country.

Drivers

• Rapid expansion of smart healthcare initiatives
• Increasing integration of AI in hospital systems
• Strong national focus on pharmaceutical innovation
• Growing investment in digital health ecosystems

Restraints

• Limited historical clinical data availability
• Dependence on imported AI technologies
• Shortage of advanced biomedical researchers

Opportunities

• Growth in AI-driven metabolic disease repurposing
• Rising collaborations with global pharma companies
• Expansion of AI-enabled national health platforms

United Arab Emirates Artificial Intelligence in Drug Repurposing Market Analysis

United Arab Emirates represented approximately 26.0% of the Asia-Pacific market in 2025 and was valued at around USD 11.44 million. The market is characterized by increasing demand for nutrition personalization and growing awareness of gut health management.

Drivers

• Strong government push for AI-first healthcare strategy
• Increasing deployment of smart hospital infrastructure
• Rising pharmaceutical research investments

Restraints

• Limited domestic drug discovery ecosystem
• High cost of advanced AI deployment
• Data integration challenges across healthcare entities

Opportunities

• Growth in AI-based precision medicine initiatives
• Rising clinical trial optimization programs
• Expansion of cross-border health data collaborations

South Africa Artificial Intelligence in Drug Repurposing Market Analysis

South Africa represented approximately 24.9% of the Asia-Pacific market in 2025 and was valued at around USD 6.67 million. The market is expanding rapidly due to rising focus on infectious disease management.

Drivers

• Increasing digital transformation in public healthcare
• Growing adoption of AI in disease research programs
• Rising focus on infectious disease management

Restraints

• Insufficient healthcare data infrastructure
• Limited funding for advanced AI systems

Opportunities

• Expansion of AI in HIV and tuberculosis drug repurposing
• Rising global research partnerships

Egypt Artificial Intelligence in Drug Repurposing Market Analysis:

Egypt accounted for approximately 25.3% of the Asia-Pacific market in 2025 and was valued at nearly USD 3.62 million. Rising adoption of digital medical technologies and expanding interest in AI-based drug development are driving market expansion across the country.

Drivers

• Growing healthcare system modernization efforts
• Increasing pharmaceutical research activities
• Rising adoption of digital medical technologies

Restraints

• Limited access to integrated clinical databases
• Regulatory and approval complexities
• Infrastructure gaps in advanced computing

Opportunities

• Growth in AI-assisted infectious disease research
• Rising international collaboration in drug discovery
• Expansion of digital health transformation programs

Israel Artificial Intelligence in Drug Repurposing Market Analysis

Israel represented approximately 25.4% of the Asia-Pacific market in 2025 and was valued at around USD 3.18 million. The market is characterized by advanced pharmaceutical R&D infrastructure.

Drivers

• Strong AI-driven biotech innovation ecosystem
• High investment in computational life sciences
• Advanced pharmaceutical R&D infrastructure

Restraints

• High R&D and operational costs
• Limited scalability for smaller biotech firms

Opportunities

• Growth in AI-based oncology drug repurposing
• Rising venture capital investment in biotech AI

Latin AmericaArtificial Intelligence in Drug Repurposing Market Analysis

Latin America accounted for approximately 2.7% of the global market in 2025 and was valued at around USD 38.46 Million. The market is witnessing gradual growth supported by rising digital transformation in healthcare systems.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Latin America Artificial Intelligence in Drug Repurposing Market Size: USD 38.46 Million
• 2035 Latin America Artificial Intelligence in Drug Repurposing Market Size: USD 381.8 Million
• Latin America Artificial Intelligence in Drug Repurposing Market CAGR (2026-2033): 25.8%

Drivers

• Increasing use of AI in biomedical research projects
• Growing adoption of cloud-based clinical platforms
• Expanding pharmaceutical innovation initiatives

Restraints

• Limited high-performance computing infrastructure
• Fragmented healthcare data ecosystems
• Low AI research funding intensity

Opportunities

• Growth in AI-based neglected disease drug repurposing
• Rising cross-border pharmaceutical collaborations
• Expansion of AI-enabled public health research networks

Brazil Artificial Intelligence in Drug Repurposing Market Analysis:

Brazil accounted for approximately 26.1% of the Asia-Pacific market in 2025 and was valued at nearly USD 12.65 million. Increasing investment in digital biomedical tools and growing integration of AI in clinical decision systems are driving market expansion across the country.

Drivers

• Expanding use of national health data platforms
• Rising adoption of AI in pharmaceutical R&D centers
• Increasing investment in digital biomedical tools
• Growing integration of AI in clinical decision systems

Restraints

• Uneven digital infrastructure across regions
• Limited interoperability of healthcare databases
• High cost of advanced AI implementation

Opportunities

• Rising collaboration with global pharma companies
• Expansion of AI-driven public health analytics

Mexico Artificial Intelligence in Drug Repurposing Market Analysis:

Mexico accounted for approximately 25.3% of the Asia-Pacific market in 2025 and was valued at nearly USD 9.04 million. Growing pharmaceutical manufacturing base and rising adoption of AI in clinical research workflows are driving market expansion across the country.

Drivers

• Increasing modernization of healthcare IT systems
• Growing pharmaceutical manufacturing base
• Rising adoption of AI in clinical research workflows
• Expanding cross-border research collaborations

Restraints

• Limited availability of structured clinical datasets
• Shortage of AI-skilled healthcare professionals
• Regulatory complexity in digital health adoption

Opportunities

• Rising partnerships with US biotech firms
• Expansion of AI-based clinical trial optimization

Argentina Artificial Intelligence in Drug Repurposing Market Analysis

Argentina represented approximately 26.3% of the Asia-Pacific market in 2025 and was valued at around USD 4.08 million. The market is characterized by growing digital health transformation efforts.

Drivers

• Increasing academic research in computational biology
• Rising use of AI in drug discovery initiatives
• Growing digital health transformation efforts
• Expanding biotech startup ecosystem

Restraints

• Economic instability affecting R&D funding
• Limited access to high-performance computing systems
• Weak integration of national health databases

Opportunities

• Growth in AI-based oncology drug repurposing
• Rising international research collaborations

Chile Artificial Intelligence in Drug Repurposing Market Analysis

Chile represented approximately 26.0% of the Asia-Pacific market in 2025 and was valued at around USD 3.31 million. The market is expanding rapidly due to growing investment in biomedical analytics tools

Drivers

• Strong focus on healthcare digital innovation
• Increasing adoption of AI in research institutes
• Growing investment in biomedical analytics tools
• Expanding public–private research partnerships

Restraints

• Limited scale of domestic pharmaceutical R&D
• High dependency on external AI platforms
• Data fragmentation across healthcare systems

Opportunities

• Growth in AI-supported infectious disease repurposing
• Rising participation in global clinical research networks
• Expansion of AI-driven healthcare analytics systems

Colombia Artificial Intelligence in Drug Repurposing Market Analysis:

Colombia accounted for approximately 26.4% of the Asia-Pacific market in 2025 and was valued at nearly USD 2.00 million. Increasing modernization of healthcare services and growing use of AI in pharmaceutical research are driving market expansion across the country.

Drivers

• Increasing modernization of healthcare services
• Growing use of AI in pharmaceutical research
• Rising investment in digital health infrastructure
• Expanding academic–industry collaborations

Restraints

• Limited funding for advanced AI research
• Lack of integrated national clinical databases
• Shortage of skilled data science professionals

Opportunities

• Rising global biotech collaborations
• Expansion of AI-enabled public health research

Peru Artificial Intelligence in Drug Repurposing Market Analysis

Peru represented approximately 25.7% of the Asia-Pacific market in 2025 and was valued at around USD 1.65 million. The market is characterized by growing interest in AI-based medical research.

Drivers

• Rising adoption of digital healthcare technologies
• Increasing pharmaceutical sector development
• Growing interest in AI-based medical research
• Expanding clinical data digitization efforts

Restraints

• Limited AI infrastructure availability
• Weak integration of healthcare data systems
• Dependence on imported technology solutions

Opportunities

• Rising international healthcare collaborations
• Expansion of digital biomedical research initiatives

Artificial Intelligence in Drug Repurposing Market Key Players: Mention the shareholding of major 5 players

Key Players	Market Share
Owkin	45.3%
BioXcel Therapeutics Inc.	13.8%
BullFrog AI Holdings, Inc.	8.6%
Delta4.ai	7.1%
Insilico Medicine	4.6%

Artificial Intelligence in Drug Repurposing Market Recent Developments

• In November 2025, Owkin, in collaboration with Gustave Roussy and Charité Comprehensive Cancer Center, unveiled a pan-European "agentic infrastructure" to AI-enable biomedical data and support AI-native biology. The initiative aims to harmonize and structure data across Europe, create biology-focused reasoning systems, and prioritize strict data protection. 
• In August 2025, Fifty1 Labs and BioSpark AI collaborated to convert over 10,000 unstructured clinical case reports into a structured, queryable database with 2,000+ real-world patient treatment-outcome pathways. This AI-powered collaboration accelerates drug repurposing and functional medicine innovation by allowing for prioritized candidate selection for chronic fatigue, neuroinflammation, and sleep disorders.
• In January 2025, Former Verbit CEO Tom Livne founded Grace, a new startup that uses advanced AI to repurpose shelved drugs. Grace hopes to raise $10-20 million in funding to accelerate the revival of drug candidates and reduce attrition across the clinical development stages. (Source: https://www.calcalistech.com/ctechnews/article/sjz7in3l1x)
• In June 2024, BioXcel Therapeutics used artificial intelligence-based drug repurposing to discover new applications for drug candidates that had stalled in development. The company accelerates therapeutic innovation by integrating approved and established drugs, clinically validated candidates, big data, and proprietary machine learning algorithms. It is focused on research and development costs, market access, and growth in neurology and immuno-oncology within the drug repurposing market. (Source: )

Artificial Intelligence in Drug Repurposing Market Regulatory Landscape Analysis:

• AI-assisted regulatory submissions
• Adaptive approval pathway utilization
• Cross-border compliance standards
• Safety and validation requirements

Artificial Intelligence in Drug Repurposing Market Patent & IP Landscape

• Machine learning model patents
• Proprietary dataset protection
• Strategic IP collaborations
• R&D innovation ecosystems

Artificial Intelligence in Drug Repurposing Market Segmentations:

Our research framework strategically segments the large molecule bioanalytical testing services market by testing methodologies, modality landscape, end-user categories, and key regional markets

By Technology

• Machine Learning/Deep Learning
• Natural Language Processing (NLP)
• Knowledge Graphs & Network-Based AI
• Generative AI & Large Language Models (LLMs)
• Computer Vision

By Component

• Software & Platforms
• Services

By Application

• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Rare & Orphan Diseases
• Other Therapeutic Areas

By End Use

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Others

By Region & Country

North America

• US
• Canada

Europe

• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Rest of EU

Asia Pacific

• China
• India
• Japan
• Australia
• South Korea
• Thailand
• Rest of APAC

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Rest of MEA

Latin America

• Brazil
• Argentina
• Mexico
• Rest of LA

Key Report Attributes	Details
Years Considered	2022 to 2035
Market Size 2025	USD 1424.5 Million
Market Size 2035	USD 14481.4 Million
Historical CAGR % (Growth rate)	XX from 2022 to 2025
Futuristic CAGR % (Growth rate)	26.10% from 2026 to 2035
Segments Covered	· By Technology · By Component · By Application · By End-Use
Regions Covered	· North America · Europe · Asia Pacific · Middle East & Africa · Latin America
Countries Covered	U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Switzerland, Netherlands, Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Singapore; Australia; Australia; Philippines; Indonesia; Brazil; Argentina; Indonesia; Chile; Colombia; Peru; South Africa; Egypt; Israel; Saudi Arabia; UAE; Kuwait
Competitive Landscape Overview	· BostonGene Corporation · BenevolentAI · Innophore · Delta4.ai · BioXcel Therapeutics Inc. · BullFrog AI Holdings, Inc. · Graphwise · Owkin, Inc · Insilico Medicine · Healx · Others
Flexible Report Customization	The study can be customized based on geography, segment analysis, company profiling, competitive benchmarking, and strategic insights.
Data Sources	Primary and secondary sources used (Company filings, trade associations, Journals, Annual report, Publications, Surveys, Investor Presentations, and much more.

Related Report

AI in Genomics Market
Artificial Intelligence in Healthcare Market
AI in Personalized Nutrition Market
Radiotheranostics Market
AI in Medical Imaging Market
Artificial Intelligence in Drug Discovery Market
Complementary and Alternative Medicine Market